CD274 and non-small cell lung carcinoma: As a second-line treatment, immunotherapy can be used in patients with locally advanced or advanced NSCLC regardless of PD-L1 expression (nivolumab or atezolizumab) or in patients with PD-L1 expression on ≥ 1% of TC (pembrolizumab) [1, 7].